var data={"title":"Minocycline: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Minocycline: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6587?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">see &quot;Minocycline: Drug information&quot;</a> and <a href=\"topic.htm?path=minocycline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Minocycline: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196900\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>CoreMino;</li>\n      <li>Minocin;</li>\n      <li>Solodyn;</li>\n      <li>Ximino</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1025436\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Tetracycline Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1025467\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">see &quot;Minocycline: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> Children &gt;8 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral immediate release:  Initial: 4 mg/kg (maximum dose: 200 mg), then 2 mg/kg/dose every 12 hours (maximum dose: 100 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial: 4 mg/kg (maximum dose: 200 mg), then 2 mg/kg/dose (maximum dose 100 mg/dose) every 12 hours; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne:</b> Adolescents: Oral immediate release: 100 mg once daily, in some patients may increase to 150 to 200 mg/day (Goulden, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne, inflammatory, non-nodular, moderate to severe:</b> Children &ge;12 years and Adolescents: Oral: Extended release tablet:  <b>Note:</b> Higher doses do not confer greater efficacy and may be associated with more acute vestibular side effects: ~1 mg/kg/dose once daily for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">45 to 49 kg: 45 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50 to 59 kg: 55 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">60 to 71 kg: 65 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">72 to 84 kg: 80 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">85 to 96 kg: 90 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">97 to 110 kg: 105 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">111 to 125 kg: 115 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">126 to 136 kg: 135 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cellulitis (purulent) infection due to community-acquired MRSA:</b> Children &gt;8 years and Adolescents: Oral: Immediate release: Initial: 4 mg/kg (maximum dose: 200 mg), then 2 mg/kg/dose (maximum dose: 100 mg/dose) every 12 hours for 5 to 10 days (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate release: Initial dose: 200 mg, followed by 100 mg every 12 hours; more frequent dosing intervals may be used (100 to 200 mg initially, followed by 50 mg 4 times daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Initial dose: 200 mg, followed by 100 mg every 12 hours; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acne, inflammatory, non-nodular, moderate to severe:</b> Extended release tablet: Oral: <b>Note:</b> Higher doses do not confer greater efficacy and may be associated with more acute vestibular side effects: ~1 mg/kg/dose once daily for 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">45 to 49 kg: 45 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50 to 59 kg: 55 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">60 to 71 kg: 65 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">72 to 84 kg: 80 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">85 to 96 kg: 90 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">97 to 110 kg: 105 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">111 to 125 kg: 115 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">126 to 136 kg: 135 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Asymptomatic meningococcal carrier state:</b> Oral: Immediate release: 100 mg every 12 hours for 5 days; <b>Note:</b> CDC recommendations do not mention use of minocycline for eradicating nasopharyngeal carriage of meningococcus (<i>Pink Book</i> [CDC 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cellulitis (purulent) infection due to community-acquired MRSA:</b> Oral: Immediate release: Initial: 200 mg, then: 100 mg every 12 hours for 5 to 10 days; maximum dose: 100 mg/dose (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chlamydial or <i>Ureaplasma urealyticum</i> infection, uncomplicated (urethral, endocervical, or rectal):</b> Oral, IV: 100 mg every 12 hours for at least 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gonococcal infection, uncomplicated (males):</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Without urethritis or anorectal infection:</i> Initial: 200 mg, followed by 100 mg every 12 hours for at least 4 days (cultures 2 to 3 days post-therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Urethritis:</i> 100 mg every 12 hours for 5 days</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">\n      <b>\n        <b>\n          <i>Mycobacterium marinum</i></b> cutaneous infection:</b> Oral: Immediate release: 100 mg every 12 hours for 6 to 8 weeks (<b>Note:</b> Optimal dosing has not been established)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Syphilis:</b> Oral immediate release tablet, IV: Initial: 200 mg, followed by 100 mg every 12 hours for 10 to 15 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;80 mL/minute:  Adults: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;80 mL/minute:  Adults: Consider decreasing dose or extending interval between doses; maximum daily dose: 200 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Not dialyzable (Brogden 1975)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, hepatotoxicity has been reported. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196875\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minocin: 50 mg, 75 mg [DSC], 100 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ximino: 90 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ximino: 135 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Combination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minocin: 50 mg [DSC], 100 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), disodium edta, fd&amp;c yellow #10 (quinoline yellow), sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minocin: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg, 75 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CoreMino: 45 mg, 90 mg, 135 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 55 mg [contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 65 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #2 (indigotine), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 80 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 105 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solodyn: 115 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #2 (indigotine), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 45 mg, 65 mg, 90 mg, 115 mg, 135 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196861\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28799613\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">see &quot;Minocycline: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocin Kit contains minocycline oral capsules packaged with T3 Calming Wipes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocin for injection contains magnesium 2.2 mEq per vial</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29447371\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Minolira (minocycline extended release tablets): FDA approved May 2017; anticipated availability is currently unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1025473\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">IV: Infuse over 60 minutes; avoid rapid administration; the injectable route should be used only if the oral route is not feasible or adequate; prolonged intravenous therapy may be associated with thrombophlebitis</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Oral: Administer with adequate fluid to decrease the risk of esophageal irritation and ulceration. Administer with or without food. Swallow pellet-filled capsule and extended release tablet whole; do not chew, crush, or split. Administer antacids, calcium supplements, iron supplements, magnesium-containing laxatives, and cholestyramine 2 hours before or after minocycline.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2026089\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule (including pellet-filled), tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from heat, light, and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release capsule: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light, moisture, and excessive heat.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release tablet: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from heat, light, and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Diluted solution in NS, D5W, D5NS, or LR is stable at room temperature for up to 4 hours or at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1025437\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocin injection, immediate release oral tablets, and oral capsules: Treatment of susceptible gram-negative and gram-positive infections involving the respiratory tract, urinary tract, and skin/soft tissue; treatment of anthrax (inhalational, cutaneous, and gastrointestinal); brucellosis; asymptomatic meningococcal carrier state; rickettsial diseases (including Rocky Mountain spotted fever, typhus fever, Q fever); nongonococcal urethritis caused by <i>Ureaplasma urealyticum</i> or <i>C. trachomatis</i>, and gonorrhea; chlamydial infections (All indications: FDA approved in ages &gt;8 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solodyn extended release tablets: Treatment of inflammatory lesions of non-nodular, moderate to severe acne vulgaris (FDA approved in ages &ge;12 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196948\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dynacin may be confused with Dyazide, Dynapen </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Minocin may be confused with Indocin, Lincocin, Minizide, niacin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196945\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, drowsiness, fatigue, malaise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute renal failure (reversible), anaphylaxis, angioedema, autoimmune hepatitis, balanitis, bulging fontanel, <i>Clostridium dificile-</i>associated diarrhea, DRESS syndrome, dysphagia, enterocolitis, eosinophilia, erythema multiforme, exacerbation of systemic lupus erythematosus, exfoliative dermatitis, fixed drug eruption, glossitis, hearing loss, hemolytic anemia, hepatic failure, hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hypersensitivity reaction, IgA vasculitis, lupus-like syndrome, malignant neoplasm of thyroid, microscopic thyroid discoloration (brown-black), mucous membrane pigmentation, myocarditis, pancreatitis, pericarditis, pneumonitis, polyarthralgia, pseudomembranous colitis, pseudotumor cerebri, pulmonary infiltrates (with eosinophilia), serum sickness, skin photosensitivity, skin pigmentation, Stevens-Johnson syndrome, thrombocytopenia, thyroid dysfunction, tooth discoloration, vasculitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196882\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to minocycline, other tetracyclines, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe liver disease; complete renal failure; myasthenia gravis; use in children &lt;13 years of age; pregnancy; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196865\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune syndromes: Lupus-like, hepatitis, and vasculitis autoimmune syndromes (including serum sickness [eg fever, arthralgia, and malaise]) have been reported; discontinue if symptoms occur and assess liver function tests, ANA, and CBC.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benign intracranial hypertension (eg, pseudotumor cerebri [PTC]): Benign intracranial hypertension (headache, blurred vision, diplopia, vision loss, and/or papilledema) has been associated with use. Women of childbearing age who are overweight or have a history of intracranial hypertension are at greater risk. Concomitant use of isotretinoin (known to cause PTC) and minocycline should be avoided. Intracranial hypertension typically resolves after discontinuation of treatment; however, permanent visual loss is possible. If visual symptoms develop during treatment, prompt ophthalmologic evaluation is warranted. Intracranial pressure can remain elevated for weeks after drug discontinuation; monitor patients until they stabilize.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Lightheadedness, dizziness, and vertigo may occur; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Symptoms usually disappear with continued therapy and when the drug is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Serious liver injury, including irreversible drug induced hepatitis and fulminant hepatic failure (sometimes fatal) have been reported with use for acne treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperpigmentation: Hyperpigmentation may occur in nails, bone, skin (including scar and injury sites), eyes, sclerae, thyroid, oral cavity, visceral tissue, and heart valves; skin and oral hyperpigmentation are independent of dose or administration duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylaxis has been reported; discontinue drug immediately and institute supportive measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; use caution in patients with renal impairment as this may lead to azotemia, hyperphosphatemia, acidosis, and possibly to drug accumulation and potential hepatotoxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Photosensitivity: May cause photosensitivity; discontinue if skin erythema occurs. Use skin protection and avoid prolonged exposure to sunlight; avoid use of use tanning equipment or UVA/B treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin rash: Rash, erythema multiforme, Stevens Johnson syndrome or eosinophilia, fever, and organ failure (Drug Rash with Eosinophilia and Systemic Symptoms [DRESS] syndrome), may occur; onset of symptoms may be delayed up to several weeks; fatal in up to 10% of cases; discontinue treatment immediately if DRESS syndrome is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Hepatotoxicity has been reported; use with caution in patients with hepatic impairment or in conjunction with other hepatotoxic drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (CrCl &lt;80 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: May cause tissue hyperpigmentation, tooth enamel hypoplasia, or permanent tooth discoloration; more common with long-term use, but observed with repeated, short courses; use of tetracyclines should be avoided during tooth development (infancy and children &le;8 years of age) unless other drugs are not likely to be effective or are contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: Do not use during pregnancy. In addition to affecting tooth development, tetracycline use has been associated with retardation of skeletal development and reduced bone growth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Magnesium content: Parenteral (IV) formulation contains magnesium; monitor serum magnesium in patients with renal impairment and signs of magnesium intoxication (eg, flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression leading to respiratory paralysis). Also use with caution and closely monitor patients with heart block or myocardial damage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Acne: The American Academy of Dermatology acne guidelines recommends minocycline be used as adjunctive treatment for moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. Concomitant topical therapy with benzoyl peroxide or a retinoid is recommended should be administered with systemic antibiotic therapy (eg, minocycline) and continued for maintenance after the antibiotic course is completed (AAD [Zaenglein 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017228\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pseudotumor cerebri has been reported rarely in infants and adolescents; use with isotretinoin has been associated with cases of pseudotumor cerebri; avoid concomitant treatment with isotretinoin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299717\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196870\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12915&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Minocycline may decrease the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: May decrease the serum concentration of Tetracyclines. Management: Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate administration.  This is of questionable significance for at least some regimens intended to treat H. pylori infections.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subsalicylate: May decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: Minocycline may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Tetracyclines may decrease the absorption of Iron Salts. Iron Salts may decrease the serum concentration of Tetracyclines. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Dimecrotate: May interact via an unknown mechanism with Tetracyclines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Minocycline may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinapril: May decrease the serum concentration of Tetracyclines. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <b> Exceptions: </b>Adapalene; Bexarotene (Topical); Tretinoin (Topical).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: May decrease the serum concentration of Tetracyclines. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the absorption of Tetracyclines. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucroferric Oxyhydroxide: May decrease the serum concentration of Tetracyclines. Management: Administer oral/enteral doxycycline at least 1 h before sucroferric oxyhydroxide.  Specific dose separation guidelines for other tetracyclines are not presently available.  No interaction is anticipated with parenteral administration of tetracyclines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zinc Salts: May decrease the absorption of Tetracyclines. Only a concern when both products are administered orally. Management: Consider doxycycline as a noninteracting tetracycline derivative. Separate dose administration of oral tetracycline derivative and oral zinc salts by at least 2 hours to minimize interaction.<b> Exceptions: </b>Zinc Chloride.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196895\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Minocycline serum concentrations are not significantly altered if taken with food or dairy products. Management: Administer without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196872\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196885\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Minocycline crosses the placenta. Tetracycline-class antibiotics may cause fetal harm following maternal use in pregnancy. Rare spontaneous reports of congenital anomalies, including limb reduction, have been reported following maternal minocycline use. Due to limited information, a causal association cannot be established. Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Mylonas 2011). Minocycline is not recommended for the treatment of Rocky Mountain Spotted Fever (Biggs 2016), Q fever (Anderson 2013), or anthrax infection (Meaney-Delman 2014) in pregnant women. When systemic antibiotics are needed for dermatologic conditions in pregnant women, other agents are preferred (Kong 2013; Murase 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2934661\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">CBC, serum BUN, creatinine, liver function tests. Observe for changes in bowel frequency. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196864\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; cell wall synthesis is not affected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196881\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely distributed to most body fluids, bile, and tissues; poor CNS penetration; deposits in fat for extended periods; V<sub>d</sub>: 0.14 to 0.7 L/kg (Zhanel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 55% to 96% (Zhanel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 90% to 100% (Zhanel 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 15 to 23 hours; 11 to 16 hours (hepatic impairment); 18 to 69 hours (renal impairment); Oral: 16 hours (range: 11 to 17 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Capsule, pellet filled: 1 to 4 hours; Tablet: 1 to 3 hours; Extended release tablet: 3.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (5% to 12% excreted unchanged) (Brogden 1975; Zhanel 2004); feces (20% to 34%) (Brogden 1975)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196884\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Ximino Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (30): $839.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mg (30): $839.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Minocin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $360.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $2,940.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Minocycline HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $169.87</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $197.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $169.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Minocin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $185.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (CoreMino Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (30): $480.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (30): $480.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mg (30): $480.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Minocycline HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (30): $605.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">65 mg (30): $1,306.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (30): $605.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">115 mg (30): $1,306.39</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">135 mg (30): $605.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Solodyn Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">55 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">65 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">105 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">115 mg (30): $1,462.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Minocycline HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $343.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $504.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (50): $300.98</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196888\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acneclin (AR, EC);</li>\n      <li>Akamin (AU);</li>\n      <li>Antinocil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Bagomicina (CL, EC);</li>\n      <li>Borymycin (MY, SG, TW);</li>\n      <li>Cyclimycin (ZA);</li>\n      <li>Cynomycin (IN);</li>\n      <li>Delnil (CL);</li>\n      <li>Dentomycin (IE);</li>\n      <li>Haicin (PH);</li>\n      <li>Klinomycin (LU);</li>\n      <li>Lederderm (DE);</li>\n      <li>Melicin (TW);</li>\n      <li>Mestacine (FR);</li>\n      <li>Micromycin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Minaxen (MT, TR);</li>\n      <li>Mino-50 (LU);</li>\n      <li>Minocin (AE, BB, BE, BH, BO, BR, CH, CN, EC, EG, ES, GB, GR, HK, ID, IE, IT, KR, KW, LU, MX, NL, PE, PH, PK, PR, PT, PY, QA, SA, UY, VE, VN);</li>\n      <li>Minocin Akne (SI);</li>\n      <li>Minocin MR (MT);</li>\n      <li>Minoclin (IL);</li>\n      <li>Minocyclin (CZ);</li>\n      <li>Minocyclin 50 Stada (DE);</li>\n      <li>Minogran (CO);</li>\n      <li>Minolin (LK);</li>\n      <li>Minoline (TW);</li>\n      <li>Minolox (VN);</li>\n      <li>Minomycin (AU, NZ);</li>\n      <li>Minosil (IE);</li>\n      <li>Minostad (AT);</li>\n      <li>Minot (CO, CR, DO, EC, GT, HN, NI, PA, PE, SV);</li>\n      <li>Minotab (LU);</li>\n      <li>Minotab 50 (BE, NZ, ZA);</li>\n      <li>Minox (IE);</li>\n      <li>Minoz MR (RO);</li>\n      <li>Mirosin (TW);</li>\n      <li>Mynocine (FR);</li>\n      <li>Parocline (FR);</li>\n      <li>Periocline (JP);</li>\n      <li>Ximino (BM)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Dermatology/American Academy of Dermatology Association, &quot;Guidelines of Care for Acne Vulgaris Management,&quot; <i>J Am Acad Dermatol</i>, 2007, 56(4):651-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/17276540/pubmed\" target=\"_blank\" id=\"17276540\">17276540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/23535757/pubmed\" target=\"_blank\" id=\"23535757\">23535757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basler RS and Lynch PJ, &quot;Black Galactorrhea as a Consequence of Minocycline and Phenothiazine Therapy,&quot; <i>Arch Dermatol</i>, 1985, 121(3):417-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/4038862/pubmed\" target=\"_blank\" id=\"4038862\">4038862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/27172113/pubmed\" target=\"_blank\" id=\"27172113\">27172113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brogden RN, Speight TM, and Avery GS, &quot;Minocycline: A Review of Its Antibacterial and Pharmacokinetic Properties and Therapeutic Use,&quot; <i>Drugs</i>, 1975, 9(4):251-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/1173232/pubmed\" target=\"_blank\" id=\"1173232\">1173232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. <i>Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book)</i>. Atkinson W, Wolfe S, Hamborsky J, eds.12th ed., second printing. Washington DC: Public Health Foundation, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, and Blumer JL, &quot;Antibiotics and Breast-Feeding: A Critical Review of the Literature,&quot; <i>Paediatr Drugs</i>, 2002, 4(12):817-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/12431134/pubmed\" target=\"_blank\" id=\"12431134\">12431134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goulden V, &quot;Guidelines for the Management of Acne Vulgaris in Adolescents,&quot; <i>Paediatr Drugs</i>, 2003, 5(5):301-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/12716217/pubmed\" target=\"_blank\" id=\"12716217\">12716217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt MJ, Salisbury EL, Grace J, et al, &quot;Black Breast Milk Due to Minocycline Therapy,&quot; <i>Br J Dermatol</i>, 1996, 134(5):943-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/8736342/pubmed\" target=\"_blank\" id=\"8736342\">8736342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. <i>Drugs</i>. 2013;73(8):779-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/23657872/pubmed\" target=\"_blank\" id=\"23657872\">23657872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &quot;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children: Executive Summary,&quot; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meaney-Delman D, Zotti ME, Creanga AA, et al. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis. 2014;20(2).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/24457117/pubmed\" target=\"_blank\" id=\"24457117\">24457117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Minocin (minocycline) [prescribing information]. Parsippany, NJ: Rempex Pharmaceuticals; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):e1-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mylonas I, &quot;Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration,&quot; <i>Arch Gynecol Obstet</i>, 2011, 283(1):7-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/20814687/pubmed\" target=\"_blank\" id=\"20814687\">20814687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pugashetti R, Shinkai K. Treatment of acne vulgaris in pregnant patients. <i>Dermatol Ther</i>. 2013;26(4):302-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/23914887/pubmed\" target=\"_blank\" id=\"23914887\">23914887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. <i>Clin Pharmacokinet</i>. 1988;15(6):355-366.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/3072140 /pubmed\" target=\"_blank\" id=\"3072140 \">3072140 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanchez AR, Rogers RS 3rd, and Sheridan PJ, &quot;Tetracycline and Other Tetracycline-Derivative Staining of the Teeth and Oral Cavity,&quot; <i>Int J Dermatol</i>, 2004, 43(10):709-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/15485524/pubmed\" target=\"_blank\" id=\"15485524\">15485524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs&rdquo;. 2002. Available at: www.who.int/maternal_child_adolescent/documents/55732/en/24074529</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhanel GG, Homenuik K, Nichol K, et al, &quot;The Glycylcyclines: A Comparative Review With the Tetracyclines,&quot; <i>Drugs</i>, 2004, 64(1):63-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/minocycline-pediatric-drug-information/abstract-text/14723559/pubmed\" target=\"_blank\" id=\"14723559\">14723559</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12915 Version 230.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F196900\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1025436\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1025467\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196875\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F196861\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F28799613\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F29447371\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1025473\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F2026089\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1025437\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F196948\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196945\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196882\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196865\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017228\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299717\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F196870\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F196895\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F196872\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F196885\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2934661\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196864\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F196881\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F196884\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F196888\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12915|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">Minocycline: Drug information</a></li><li><a href=\"topic.htm?path=minocycline-patient-drug-information\" class=\"drug drug_patient\">Minocycline: Patient drug information</a></li></ul></div></div>","javascript":null}